The following are clinical trials in association with the University of San Diego Cancer Center
The UCSD hematologic malignancy program at the Moores Cancer Center is actively involved in the development of new and exciting strategies for the treatment of CLL. Listed below are clinical protocols that are open and actively accruing:
First-line Studies:
A Study of Combined High Dose - Methylprednisolone and Rituximab as First-Line Treatment of Patients with Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia [UCSD-060256]
A Two-Arm, CLL Research Consortium - (CRC014) Multi-Center Trial of Revlimid and Rituximab, for First-Line Treatment in Patients with Chronic Lymphocytic Leukemia [UCSD-070692]
Previously Treated Studies:
A Phase II Study of Ofatumumab - (Arzerra) in Combination with High-dose Methylprednisolone in Patients with Relapsedor Refractory Chronic Lymphocytic Leukemia [UCSD-100429]
A Phase Ib Study of ISF35 in Combination - With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p-CLL
A Phase I/II Study of AMD3100 (Mozobil) and Rituximab in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia [MOZ00207]
A Phase I Study Evaluating the Safety of ABT-263 (Navitoclax) in Combination with Either Fludarabine/Cyclophosphamide/ Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia [UCSD-090285]
A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid) Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia [CC-5013-CLL-009]
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 (Navitoclax) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia [UCSD-070581]
CAM203: Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients with Previously Treated B Cell Chronic Lymphocytic Leukemia [UCSD-080730]
A Multicenter, Open-Label, Single-Arm Study of Weekly Alvocidib (Flavopiridol) in Patients with Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising from CLL [UCSD-061346]
A Two-Arm, CLL Research Consortium (CRC022) Multi-Center Trial of Revlimid and Rituximab, for the Treatment of relapsed or refractory Patients with Chronic Lymphocytic Leukemia [UCSD-100205]
Non-Therapeutic:
CLL Research Consortium Tissue Core Sample Collection Study [CRC000]
CLL Research Consortium Familial Tissue Core Sample Collection Study [CRC000-1]
TRIAL TYPES
FIRST-LINE: These studies are for patients that have not received treatment for CLL
PREVIOUSLY TREATED: These studies are for patients that have had previous treatment for CLL.
NON-THERAPEUTIC: These are studies that involve no treatment. These are usually studies that involve the collection of biospecimens used for laboratory research.
FOR MORE INFO:
Please contact Shiela Hoff, R.N. at UCSD (858) 822-5360 to see if you might be eligible for one of these studies.
To schedule an appointment in the UCSD CLL clinic with either Drs. Kipps, James, or Castro please contact Mary Carpenter at: (858) 822-5635
